Vivian G. Oehler

Oncology

1959 NE Pacific St
Seattle, WA 98195

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Rooted in reality, living with hope: post-treatment fertility preservation.

Rooted in reality, living with hope: post-treatment fertility preservation.

Journal: Haematologica

Published: May 06, 2026

Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.

Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.

Journal: Leukemia

Published: March 05, 2026

Olverembatinib: real progress in BCR::ABL1 leukemia?

Olverembatinib: real progress in BCR::ABL1 leukemia?

Journal: Haematologica

Published: March 03, 2026

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

Journal: Leukemia

Published: January 16, 2026

Biology-Directed Therapy for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangements.

Biology-Directed Therapy for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangements.

Journal: NEJM evidence

Published: August 26, 2025

Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.

Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.

Journal: Leukemia

Published: August 26, 2025

Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing.

Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing.

Journal: Haematologica

Published: August 13, 2025

Spatial proteomics and transcriptomics characterization of tissue and multiple cancer types including decalcified marrow.

Spatial proteomics and transcriptomics characterization of tissue and multiple cancer types including decalcified marrow.

Journal: Cancer biomarkers : section A of Disease markers

Published: March 20, 2025

Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.

Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.

Journal: Leukemia

Published: February 17, 2025

Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.

Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.

Journal: Leukemia

Published: February 17, 2025

Olverembatinib in chronic myeloid leukemia-Review of historical development, current status, and future research.

Olverembatinib in chronic myeloid leukemia-Review of historical development, current status, and future research.

Journal: Cancer

Published: January 28, 2025

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.

Journal: JAMA oncology

Published: November 21, 2024

Showing 1-12 of 67

Last Updated: 09/26/2026